Endonovo Therapeutics (ENDV) Change in Accured Expenses (2018 - 2023)
Endonovo Therapeutics has reported Change in Accured Expenses over the past 9 years, most recently at -$219236.0 for Q3 2023.
- Quarterly results put Change in Accured Expenses at -$219236.0 for Q3 2023, down 339.85% from a year ago — trailing twelve months through Sep 2023 was $21675.0 (down 91.82% YoY), and the annual figure for FY2022 was $269391.0, down 46.89%.
- Change in Accured Expenses for Q3 2023 was -$219236.0 at Endonovo Therapeutics, down from $228760.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for ENDV hit a ceiling of $888986.0 in Q4 2019 and a floor of -$219236.0 in Q3 2023.
- Median Change in Accured Expenses over the past 5 years was $101244.0 (2021), compared with a mean of $141428.9.
- Biggest five-year swings in Change in Accured Expenses: skyrocketed 680.29% in 2020 and later plummeted 339.85% in 2023.
- Endonovo Therapeutics' Change in Accured Expenses stood at $888986.0 in 2019, then tumbled by 87.25% to $113312.0 in 2020, then tumbled by 128.54% to -$32338.0 in 2021, then rose by 13.85% to -$27859.0 in 2022, then plummeted by 686.95% to -$219236.0 in 2023.
- The last three reported values for Change in Accured Expenses were -$219236.0 (Q3 2023), $228760.0 (Q2 2023), and $40010.0 (Q1 2023) per Business Quant data.